Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage

Trial Profile

Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Radgocitabine (Primary) ; Azacitidine; Cladribine; Cytarabine; Decitabine; Etoposide; Fludarabine; Idarubicin; Mitoxantrone; Venetoclax
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Delta-Fly Pharma
  • Most Recent Events

    • 30 Jan 2024 According to a Delta-Fly Pharma media release, company plans to shows the Interium results when the data is ready to disclose as there are long term surviving patients (N=150) in this study so company continue to follow up these patients without any data cut-off for the time being to determine the final overall survival results of the study.
    • 30 Jun 2023 According to a Delta-Fly Pharma media release, the interim analysis for the study shall be done based on outcome measurements (complete remission rate, overall survival and safety) as follows- The 1st data processing of this study shall be done on the middle July in 2023 and the 2nd data processing shall be done by the end of November 2023.Studys abstract shall be submitted by the principal investigator at the annual meeting of ASH 2023 and at the annual meeting of ASCO 2024.
    • 15 May 2023 According to a Delta-Fly Pharma media release, 150 patients have been enrolled and the 1st interim analysis of this study shall be done for NDA approval to the FDA in US soon after confirmation of the superiority of DFP-10917 arm.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top